期刊
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
卷 26, 期 4, 页码 319-324出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jop.2010.0024
关键词
-
资金
- Bureau of Traditional Chinese Medicines in Heilongjiang Province [2005AEQXJ070]
Purpose: To determine whether mangiferin can enter the eye, because the eye possesses the unique blood-ocular barrier. Methods: Due to the low solubility of mangiferin, hydroxypropyl-beta-cyclodextrin was applied to improve the absorbance. A reversed-phase high-performance liquid chromatography assay for mangiferin in rat plasma and eye fluid was developed. The mobile phase consisted of methanol-0.6% glacial acetic acid (27: 73, v/v) at a flow rate of 1.0mL/min. Results: Peak areas of mangiferin were linear over a concentration range of 0.40-20.00 mg/mL in blood samples and a range of 0.10-5.00 mg/mL in eye samples, respectively. Intra- and interassay precision and accuracy of mangiferin fell well within the predefined limits of acceptability (<15%). The recovery was 81.12%-87.18% in the plasma and 79.96%-85.52% in the eye, respectively. The analytical method had excellent sensitivity using a small sample volume (20 mu L) with the lower limit of quantification, 0.4 and 0.10 mu g/mL for plasma and eye, respectively. Pharmacokinetic parameters of mangiferin in plasma were obtained as follows: T-max = 7h, C-max = (4.43 0.62) mu g/mL. The time point of 7 h was chosen for eye sample detection, as it had maximum plasma concentration. The concentration of mangiferin in the eye tissue 7 h after oral administration was (0.34 +/- 0.13) mu g/mL (n = 6), coefficient of variation % = 38.24%. Conclusions: Mangiferin can pass the blood-ocular barrier and is suitable to be used as an antioxidant in eye diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据